Given the high incidence of age-related macular degeneration (AMD)—with some 10 to 11 million patients affected, 2 million of which have severe visual loss—the need for treatments to restore vision is clear.
This article was reviewed by Arshad M. Khanani, MD, MA, and Joshua Mali, MD
Anti-VEGF injections may be associated with acute IOP spikes and chronic IOP rise in patients, and these increases in IOP need to be acknowledged and managed, according to Matthew Schlenker MD, MSc.
Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD),
According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.
The MDA is a nonprofit health organization dedicated to educating and empowering patients with AMD.
Results from two large, phase III studies (HAWK and HARRIER) have found brolucizumab 6 mg (Novartis) produced better anatomical outcomes than aflibercept-in terms of retinal thickness, intraretinal fluid (IRF), and/or subretinal fluid (SR